TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 and Renal Disease RUBY-I Phase 3b Treatment-Naive Pockros.

Advertisements

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.

Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

Early Evolution and Correlates of Urine Albumin Excretion in Patients Presenting With Acutely Decompensated Heart FailureClinical Perspective by Satoshi.

The DANAMI-2 Trial Danish Trial in Acute Myocardial Infarction-2

TNT: Baseline and final LDL cholesterol levels

End point Patients >75 y with renal insufficiency

51st Annual Scientific Session for the LIFE Investigators

Oana Dickinson et al. JACEP 2016;2:

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Marwan Badri et al. JACEP 2015;1:

Management of hypertension in patients with chronic kidney disease

Mean eGFR among survivors after CABG surgery vs all-cause deaths

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Creatinine clearance in cases and controls

Kenshi Hayashi et al. JACEP 2016;2:

Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM

Nat. Rev. Cardiol. doi: /nrcardio

Time point Difference in systolic BP (mm Hg) p

Thomas C. Crawford et al. JACEP 2017;3:

Thomas C. Crawford et al. JACEP 2017;j.jacep

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Mohit K. Turagam et al. JACEP 2017;3:

Predictors of disease progression in patients with CKD

Moussa Mansour et al. JACEP 2017;3:

Leonard M. Rademakers et al. JACEP 2016;2:

Jordan B. King et al. JCHF 2016;4:

Nicolaj C. Hansson et al. JACC 2016;68:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Kenshi Hayashi et al. JACEP 2016;2:

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

Classification by HtTKV0 and age at HtTKV0 predicts the change in eGFR over time in class 1 patients. Classification by HtTKV0 and age at HtTKV0 predicts.

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Disposition of Patients in the Atherogenic Dyslipidemia Study

Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD

Leo F. Buckley et al. JCHF 2016;4:1-8

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Alan Rozanski et al. JIMG 2017;10:

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Distribution of responses to the knowledge questions.

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Amir A. Mahabadi et al. JIMG 2017;10:

Ann M. O'Hare, MA, MD American Journal of Kidney Diseases

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

Risk factors Odds ratio 95% CI p Age >75 (referent: age 46-60) 2.17

Maxime Berthelot-Richer et al. JIMG 2016;9:

Evan M. Zahn et al. JCIN 2016;9: Relationship Between Patent Ductus Arteriosus Closure and Left Ventricular Ejection Fraction The graph depicts.

Change in total kidney volume and renal function over 3 years of tolvaptan compared with matched control and their correlation for individual subjects.

Maria R. Costanzo et al. JCHF 2016;4:

Plots of average estimated and measured GFR vs

Patient selection process in the present study.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Bias with estimated GFR (eGFR) by age (years).

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Correlation between change in blood pressure (BP) and a rapid annual decline in kidney function (≥3 mL/min/1.73 m2/year) (logistic regression) (n=7283).

Stefan Toggweiler et al. JCIN 2016;9:

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Intersubject distribution of eGFR slope (left) and mGFR slope (right).

Presentation transcript:

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin p eGFR (MDRD), % increase 5.6 8.4 <0.0001 Shepherd J et al. American College of Cardiology 2006 Scientific Sessions; March 13, 2006; Atlanta, GA. Abstract 808-3

TNT post hoc analysis: Patients with improvement or decline from baseline eGFR by treatment group Measure 10-mg atorvastatin 80-mg atorvastatin p Patients with improvement in GFR from <60 mL/min per 1.73m2 (%) 37 45 0.0004 Patients with decline in eGFR from >60 mL/min per 1.73m2 (%) 9 7 <0.001 Shepherd J et al. American College of Cardiology 2006 Scientific Sessions; March 13, 2006; Atlanta, GA. Abstract 808-3